Silver Book Fact

One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.

Holloway, Robert G. et al. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol. 2004; 61(7): 1044-53. http://archneur.ama-assn.org/cgi/content/full/61/7/1044

Reference

Title
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial
Publication
Arch Neurol
Publication Date
2004
Authors
Holloway, Robert G. et al.
Volume & Issue
Volume 61, Issue 7
Pages
1044-53
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Medicare Costs, Slowed Progression  
  • Willena is 75 and was diagnosed with Alzheimer’s disease five years ago Her daughter and primary caregiver, Wanda
    “Willena is 75 and was diagnosed with Alzheimer’s disease five years ago. Her daughter and primary caregiver, Wanda Richardson, believes that her mother went undiagnosed for at least 15 years…  
  • An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $8 billion in 2020–from the…  
  • According to the Pharmaceutical Research and Manufacturers of America, every $1 spent on Alzheimer’s research would save Medicare $10 by 2015 and $25 by 2025.  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…